SecBot SecBot
SECBOTREPLAY Home › Report › TNGX

TNGX · Tango Therapeutics is raising approximately $566.5 million in net…

Tango Therapeutics, Inc. · 424B5 filed Jun 10, 2026 at 17:21 ET

At the news

MIXEDIMPACT 6/10

424B5 filed Jun 10, 2026 at 17:21 ET

Tango Therapeutics is raising approximately $566.5 million in net proceeds through a public offering of 18,166,667 shares of common stock at $30.00 per share and pre-funded warrants to purchase 1,833,395 shares. The offering priced at a 4.9% discount to the prior closing price of $31.56, resulting in immediate and substantial dilution of $24.10 per share to new investors. The capital raise follows highly positive Phase 1/2 clinical data for its lead candidate vopimetostat in combination with RAS inhibitors, showing a 92% objective response rate in pancreatic cancer, which positioned the company to advance into Phase 3 development. The proceeds are expected to fund operations into 2030 including a pivotal trial and potential commercialization. The large dilutive offering paired with very strong clinical data creates a mixed signal for the stock.

  • Offering of 18,166,667 shares of common stock at $30.00 per share
  • Pre-funded warrants to purchase 1,833,395 shares at $29.999 per warrant
  • Net proceeds of approximately $566.5 million ($651.6 million if underwriters exercise full option for 3,000,009 additional shares)
  • Offering price at a ~4.9% discount to last sale of $31.56 on June 9, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access